The ROE as of November 2024 (TTM) for Metacrine, Inc. (MTCR) is -83.52%

According to Metacrine, Inc.’s latest financial reports and current stock price. The company's current ROE is -83.52%. This represents a change of 299.76% compared to the average of -20.89% of the last 4 quarters.

Metacrine, Inc. (MTCR) Historical ROE (quarterly & annually)

How has MTCR ROE performed in the past?

The mean historical ROE of Metacrine, Inc. over the last ten years is -14.98%. The current -83.52% ROE has changed 457.65% with respect to the historical average. Over the past ten years (40 quarters), MTCR's ROE was at its highest in in the December 2019 quarter at 9.45%. The ROE was at its lowest in in the September 2021 quarter at -38.89%.

Metacrine, Inc. (MTCR) ROE by Quarter and Year

Discovering the peaks and valleys of Metacrine, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Metacrine, Inc. (MTCR) Average ROE

How has MTCR ROE performed in the past?

The current ROE of Metacrine, Inc. (MTCR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Metacrine, Inc. (MTCR) ROE vs. Peers

How is MTCR’s ROE compared to its peers?

Metacrine, Inc.’s ROE is greater than Magenta Therapeutics, Inc. (-61.71%), greater than Protara Therapeutics, Inc. (-55.03%), greater than TRACON Pharmaceuticals, Inc. (-237.65%), less than Satsuma Pharmaceuticals, Inc. (133.88%), greater than Neoleukin Therapeutics, Inc. (-47.64%), greater than CytomX Therapeutics, Inc. (-27.44%), greater than Assembly Biosciences, Inc. (-121.55%), greater than Instil Bio, Inc. (-55.57%), greater than Nuvation Bio Inc. (-98.79%), less than Vaccinex, Inc. (1.11%), greater than Monopar Therapeutics Inc. (-110.60%), greater than Miromatrix Medical Inc. (-119.21%), greater than Surrozen, Inc. (-178.66%), greater than Anebulo Pharmaceuticals, Inc. (-138.92%), less than ZIVO Bioscience, Inc. (673.84%), greater than Indaptus Therapeutics, Inc. (-146.70%),

Build a custom stock screener for Metacrine, Inc. (MTCR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Metacrine, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Metacrine, Inc. (MTCR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Metacrine, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.